Roche's Tecentriq scores again on a pivotal frontline lung cancer trial, positioning them against Merck, Bristol-Myers
Roche $RHHBY nailed some badly needed success in its late-stage campaign to build a market for its PD-L1 drug Tecentriq today, posting a win for its Phase III IMpower130 combination study on both overall survival as well as progression-free survival for a key group of lung cancer patients.
Combined with chemo and Abraxane, investigators say that the Tecentriq combo significantly extended the lives of patients in the frontline setting for advanced non-squamous non-small cell lung cancer. We won’t get to see data until a future conference, but IMpower130 has been widely viewed as critical to Roche’s plans in the oncology field, where the pharma giant has been watching Merck $MRK and Bristol-Myers Squibb make blockbuster advances.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.